Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $COYA alert in real time by email

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024.

Corporate Highlights FY2024 to Date

  • Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD)
  • Announced that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination in patients with Frontotemporal Dementia (FTD)
  • Announced positive results from an investigator initiated double-blind study of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD) at the Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid. The study was titled, "A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer's Disease"
  • Aligned with FDA on the non-clinical data needed to support the planned randomized, double-blind, placebo-controlled, Phase 2b trial of COYA-302 in patients with Amyotrophic Lateral Sclerosis (ALS)
  • Announced expansion of pipeline- COYA 303; COYA 301 in combination with GLP-1 Receptor Agonist for treatment of inflammatory diseases and filing of new intellectual property portfolio for the combination

Financial Highlights FY 2024

  • Raised $10.0M in a private placement of 1.38M shares of common stock. The majority of investors in the offering were existing institutional shareholders of company
  • Received $5.0 million strategic investment by the Alzheimer's Drug Discovery Foundation (ADDF) to help support the development of COYA 302 for the treatment of Frontotemporal Dementia (FTD)
  • Received $3.85 million from the previously announced First Amendment and License Agreement with Dr. Reddy's Laboratories, Inc., which is earmarked for funding the first Phase 2 clinical trial of COYA 302 in ALS in the United States. The original agreement was entered into on December 5, 2023.

Upcoming Expected Catalysts for 2025

  • Q2 2025: Submission of additional nonclinical data to support the start of the COYA-302 Phase 2 trial in patients with ALS
  • Upon IND acceptance and first patient dosing of COYA-302 in ALS, eligible to receive milestone payments of $8.4 million from strategic partner, Dr. Reddy's Laboratories (DRL)
  • Q2 2025: Publication of COYA-303 combination mechanistic data
  • Q2 2025: Publication of data documenting role of inflammation in Parkinson's Disease
  • Q2 2025: ALS Biomarker data. Publication of longitudinal data on Neurofilament Light Chain (NfL) and oxidative stress markers in patients with ALS
  • 2H 2025: Additional single cell proteomics data from the completed investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD)
  • 2H 2025: Top-line clinical data release for an investigator-initiated trial combining LD IL-2 + CTLA4-Ig in patients with FTD
  • 2H 2025: Filing of IND for the COYA-302 Phase 2 trial in patients with FTD*

    (*Clinical trial initiated upon FDA IND approval)

Coya CEO Arun Swaminathan, Ph.D. commented, "We remain encouraged by the progress we made in 2024 and are well positioned for continued success in 2025. We continue to expand our pipeline while making significant progress on our ongoing programs in neurodegenerative diseases with high unmet need, and we are on track to initiate the randomized, double-blind controlled Phase 2b trial in patients with ALS upon IND acceptance.

"Our drug candidates all target neuroinflammation, which we see as a key driving factor towards disease progression in the neurological conditions we are addressing. Moreover, our approach to potential combination therapies for treatment of these neurodegenerative diseases differentiates us from other companies and offers, what we believe, a more potent treatment paradigm that could potentially lead to new options for patients and create meaningful shareholder value.

"The strong scientific and clinical rationale, our strong cash position and potential for new business development opportunities all together strengthens our optimism about our ability to execute on our corporate, clinical and regulatory goals and continue to build value. I look forward to sharing additional corporate, clinical, and regulatory progress as appropriate," concluded Swaminathan.

Coya CMO, Dr. Fred Grossman said, "As we have indicated in the past, we expect 2025 to hold important milestones for the Company, including initiating the phase 2b trial of COYA 302, which is the combination of LD-IL2 and CTLA 4 IG, in ALS patients. We are on track for submission of all required nonclinical data to the FDA to support the initiation of the Phase 2 trial in patients with ALS. Additionally, we will be submitting an IND for a phase 2b study of COYA 302 in FTD patients. Clinical data from an investigator initiated clinical trial of combination of LD IL-2 and CTLA 4 IG will be reported and will support the planned phase 2b trial of COYA 302 n FTD."

Financial Results

As of December 31, 2024, Coya had cash and cash equivalents of $38.3 million.

Research and development (R&D) expenses were $11.9 million for the year ended December 31, 2024, compared to $5.5 million for the year ended December 31, 2023. The change was primarily due to a $5.0 million increase in our preclinical expenses, a $1.1 million increase in internal research and development expenses, and a $0.3 million increase in costs attributable to our sponsored research agreement with Houston Methodist Hospital.

General and administrative expenses were $8.9 million for the year ended December 31, 2024, and $7.8 million for the year ended December 31, 2023, a change of approximately $1.1 million. The increase was primarily due to a $1.2 million increase in payroll and employee related benefits, a $0.3 million increase in franchise taxes and license fees and $0.2 million increase in our investor and public relations costs, partially offset by a $0.2 million decrease in insurance fees and a $0.4 million decrease in professional service fees.

Net loss was $14.9 million for the year ended December 31, 2024, compared to net loss of $8.0 million for the year ended December 31, 2023.

About Coya Therapeutics, Inc.

Headquartered in Houston, TX, Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ("Tregs") to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system.

Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya's therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

COYA 302 – the Company's lead biologic investigational product or "Pipeline in a Product" – is a proprietary combination of COYA 301 (Coya's proprietary LD IL-2) and CTLA4-Ig for subcutaneous administration with a unique dual mechanism of action that is now being developed for the treatment of Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Parkinson's Disease, and Alzheimer's Disease. Its multi-targeted approach enhances the number and anti-inflammatory function of Tregs and simultaneously lowers the expression of activated microglia and the secretion of pro-inflammatory mediators. This synergistic mechanism may lead to the re-establishment of immune balance and amelioration of inflammation in a sustained and durable manner that may not be achieved by either low-dose IL-2 or CTLA4-Ig alone.

For more information about Coya, please visit www.coyatherapeutics.com.

Forward-Looking Statements

This press release contains "forward-looking" statements that are based on our management's beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," and similar expressions are intended to identify forward-looking statements.

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to risks associated with the impact of COVID-19; the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on third party manufacturers; the success of competing therapies or products that are or may become available; our ability to attract and retain key scientific or management personnel; our ability to identify additional product candidates with significant commercial potential consistent with our commercial objectives; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or will occur. We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

BALANCE SHEETS

(Audited)

 

 

December 31,

 

2024

2023

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash equivalents

$

38,339,762

 

$

32,626,768

 

Collaboration receivables

 

-

 

 

7,500,000

 

Prepaids and other current assets

 

5,968,666

 

 

1,069,557

 

Total current assets

 

44,308,428

 

 

41,196,325

 

Fixed assets, net

 

38,588

 

 

65,949

 

Total assets

$

44,347,016

 

$

41,262,274

 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

$

1,588,128

 

$

1,155,656

 

Accrued expenses

 

1,388,060

 

 

2,973,215

 

Deferred collaboration revenue

 

848,286

 

 

923,109

 

Total current liabilities

 

3,824,474

 

 

5,051,980

 

Deferred collaboration revenue

 

945,447

 

 

574,685

 

Total liabilities

 

4,769,921

 

 

5,626,665

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

Series A convertible preferred stock, $0.0001 par value: 10,000,000 shares authorized, none issued and outstanding as of December 31, 2024 and 2023

 

-

 

 

-

 

Common stock, $0.0001 par value; 200,000,000 shares authorized; 16,707,441 and 14,405,325 shares issued and outstanding as of December 31, 2024 and 2023, respectively

 

1,671

 

 

1,441

 

Additional paid-in capital

 

80,312,594

 

 

61,501,801

 

Subscription receivable

 

-

 

 

(11,250

)

Accumulated deficit

 

(40,737,170

)

 

(25,856,383

)

Total stockholders' equity

 

39,577,095

 

 

35,635,609

 

Total liabilities and stockholders' equity

$

44,347,016

 

$

41,262,274

 

STATEMENTS OF OPERATIONS

(Audited)

 

 

Years Ended December 31,

 

2024

2023

Collaboration revenue

$

3,554,061

 

$

6,002,206

 

Operating expenses:

 

 

 

 

Research and development

 

11,865,654

 

 

5,501,527

 

In-process research and development

 

25,000

 

 

543,186

 

General and administrative

 

8,885,757

 

 

7,833,481

 

Depreciation

 

27,361

 

 

27,361

 

Total operating expenses

 

20,803,772

 

 

13,905,555

 

Loss from operations

 

(17,249,711

)

 

(7,903,349

)

Other income:

 

 

 

 

Other income, net

 

1,648,637

 

 

639,365

 

Pre-tax loss

 

(15,601,074

)

 

(7,263,984

)

Income tax benefit (expense)

 

720,287

 

 

(723,852

)

Net loss

$

(14,880,787

)

$

(7,987,836

)

 

 

 

 

 

Share information:

 

 

 

 

Net loss per share of common stock, basic and diluted

$

(0.98

)

$

(0.79

)

Weighted-average shares of common stock outstanding, basic and diluted

 

15,238,919

 

 

10,163,850

 

STATEMENTS OF CASH FLOWS

(Audited)

 

 

Years Ended December 31,

 

2024

2023

Cash flows from operating activities:

 

 

 

 

Net loss

$

(14,880,787

)

$

(7,987,836

)

Adjustment to reconcile net loss to net cash used in operating activities:

 

 

 

 

Depreciation

 

27,361

 

 

27,361

 

Stock-based compensation, including the issuance of restricted stock

 

2,663,539

 

 

872,248

 

Acquired in-process research and development

 

25,000

 

 

543,186

 

Changes in operating assets and liabilities:

 

 

 

 

Collaboration receivable

 

7,500,000

 

 

(7,500,000

)

Prepaids and other current assets

 

(4,899,109

)

 

181,707

 

Accounts payable

 

477,450

 

 

298,816

 

Accrued expenses

 

(1,498,215

)

 

877,913

 

Deferred collaboration revenue

 

295,939

 

 

1,497,794

 

Net cash used in operating activities

 

(10,288,822

)

 

(11,188,811

)

Cash flows from investing activities:

 

 

 

 

Purchase of in-process research and development assets

 

(25,000

)

 

(543,186

)

Net cash used in investing activities

 

(25,000

)

 

(543,186

)

Cash flows from financing activities:

 

 

 

 

Proceeds from sale of common stock from 2023 Private Placement, net of offering costs

 

-

 

 

24,084,805

 

Proceeds from issuance of common stock upon IPO, net of offering costs

 

-

 

 

14,250,311

 

Payment of financing costs related to the 2023 Private Placement

 

(131,918

)

 

-

 

Proceeds from subscription receivable

 

11,250

 

 

-

 

Proceeds from the exercise of stock options

 

1,975

 

 

89,947

 

Proceeds from the exercise of warrants

 

2,141,128

 

 

-

 

Proceeds from sale of common stock, net of offering costs

 

14,004,381

 

 

-

 

Net cash provided by financing activities

 

16,026,816

 

 

38,425,063

 

Net increase in cash and cash equivalents

 

5,712,994

 

 

26,693,066

 

Cash and cash equivalents as of beginning of the year

 

32,626,768

 

 

5,933,702

 

Cash and cash equivalents as of end of the year

$

38,339,762

 

$

32,626,768

 

 

 

 

 

 

Supplemental disclosures of non-cash financing activities:

 

 

 

 

Conversion of convertible preferred stock upon IPO

$

-

 

$

8,793,637

 

Conversion of convertible promissory notes upon IPO

$

-

 

$

12,965,480

 

Subscription receivable related to warrant exercise

$

-

 

$

11,250

 

Financing costs related to the 2023 Private Placement in accrued expenses and accounts payable

$

-

 

$

131,918

 

 

Investor Contact

David Snyder

david@coyatherapeutics.com

CORE IR

Bret Shapiro

brets@coreir.com

561-479-8566

Media Contact

Kati Waldenburg

media@coyatherapeutics.com

212-655-0924

Get the next $COYA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COYA

DatePrice TargetRatingAnalyst
12/4/2024$15.00Buy
D. Boral Capital
More analyst ratings

$COYA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

    Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated "Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer's disease" Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer's disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna. The presentation, titled, "A Phase II Clinical Trial o

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

    Regulatory T cell-derived exosomes (Treg exosomes) have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function The work planned includes GMP processes and manufacturing activities and the production of larger-scale clinical batches in the fourth quarter of 2025, in preparation for a first in human study Funded by the Johnson Center for Cellular Therapeutics, Hop On A Cure, and Energy Transfer, with Coya holding exclusive rights

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD) Announced that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combinat

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$COYA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$COYA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$COYA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$COYA
SEC Filings

See more

$COYA
Leadership Updates

Live Leadership Updates

See more
  • Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

    Secretary Ross has over 55 years' experience as a business leader, banker, and investor and is the former Chairman and Chief Strategy Officer of WL Ross & Co. Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross's extensive experience in both the business and investment community to help guide strategic partnering activities, capital markets initiatives and drug development programs. S

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Coya Therapeutics' CEO Dr. Howard Berman's Letter to Stockholders

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. Dear Fellow Stockholders, As the year comes to a close, I want to take a moment to reflect on Coya's accomplishments and share our strategic vision for the coming year. We set ambitious goals at the beginning of 2023 and I am pleased to say that our team rose to the occasion. Throughout the year, we notched several "wins," culminating in a transformative licensing transaction, announced December 6th, 2023, with Dr

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Coya Therapeutics Announces $26.5 Million Private Placement

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules. The offering is expected to close on or about December 11, 2023, subject to the satisfaction of customary closing conditions. The financing included participation by former U.S. Secretary of Commerce Wi

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$COYA
Financials

Live finance-specific insights

See more
  • Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Low Dose IL-2 in patients with mild-to-moderate Alzheimer's Disease (AD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at the Houston Methodist Hospital and is funded by the Gates Foundation and Alzheimer's As

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive results from a proof-of-concept (PoC), open-label, investigator-initiated clinical study of low dose interleukin-2 (ld IL-2) + CTLA4 Ig in Amyotrophic Lateral Sclerosis (ALS) illustrating enhancement of Treg function during the treatment period, halting of disease progression at 24 weeks and minimal decline a

    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

$COYA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more